ArticleBritish journal of pain2022
Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.
Article in British journal of pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.Pharmacology research & perspectives · 2026Review
- No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain.Nature communications · 2026Article
- Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Dialogues in clinical neuroscience · 2025Review
- Psychedelics and Headache Disorders: an Update.Current neurology and neuroscience reports · 2025Review
- Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.Psychiatry and clinical psychopharmacology · 2025Article
- Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models.bioRxiv : the preprint server for biology · 2025Article
- Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.ACS chemical neuroscience · 2025Review
- Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.British journal of pain · 2025Article
- Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.Psychedelic medicine (New Rochelle, N.Y.) · 2025Review
- Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.Cancer medicine · 2025Review
- Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- LSD Modulates Proteins Involved in Cell Proteostasis, Energy Metabolism and Neuroplasticity in Human Cerebral Organoids.ACS omega · 2024Article
- Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several studies and reports have shown the potential analgesic use of serotonergic psychedelics in cancer pain, phantom limb pain and cluster headache, evidence supporting their use for chronic pain is still limited. The past years have seen a considerable renewal of interest toward the therapeutic use of these compounds for mood disorders, resulting in a marked increase in the number of people turning to psychedelics in an attempt to self-medicate a health condition or improve their wellbeing. In western countries particularly, this population of users overlaps substantially with chronic pain sufferers, representing a unique opportunity to evaluate the effects these compounds have on pain and wellbeing. Here, we report results from an online survey conducted between August 2020 and July 2021 in a population of 250 chronic pain sufferers who had experience with psychedelics, either in microdoses (small sub-hallucinogenic doses), macrodoses (hallucinogenic doses), or both. Macrodoses, while less often used for analgesic purposes than microdoses, were reported to induce a higher level of pain relief than both microdoses and conventional pain medications (including opioids and cannabis). Although the effects were weaker and potentially more prone to expectation bias than with macrodoses, our results also suggested some benefits of psychedelics in microdoses for pain management. The reported analgesic effect appeared unrelated to mood improvements associated with psychedelic use, or the advocacy of psychedelic use. Taken together, our findings indicate interesting potential analgesic applications for psychedelics that warrant further clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.